Information Provided By: 
Fly News Breaks for April 4, 2016
EXEL
Apr 4, 2016 | 08:54 EDT
As noted earlier, Stifel upgraded Exelixis to Buy from Hold. The firm expects the FDA to approve the company's cabozantinib drug for renal cell carcinoma sooner than expected, and predicts that the drug's commercial launch will exceed expectations. Stifel also believes that the company's pipeline can boost its results beyond expectations. Target $7.
News For EXEL From the Last 2 Days
There are no results for your query EXEL
